Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Methotrexate price, strengths & recalls

Generic of Rasuvo, Trexall, Xatmep, Otrexup

Pharmacies pay $4.90 for 30 tablets of Methotrexate 2.5 mg tablet this week, and from $3.50 to $31.25 across its 4 priced strengths and forms. 28 manufacturers make it. It is in shortage (unavailable). 1 recall is ongoing. Its official label last changed on October 30, 2026.

Unavailable1 open recallGeneric
Pharmacies pay$4.90for 30 tablets of 2.5 mg tablet+3.5% in 4 weeks
Fair cash price
$16.14
Strengths
4
Makers
28
Updated
Nov 11

Methotrexate price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
25 mg/mL injection$3.12$31.25 / 10 mL-1.8%-2.7%
25 mg/mL, 10 mL injection$0.7020$7.02 / 10 mLNo change-0.9%
25 mg/mL, 2 mL injection$1.75$3.50 / 2 mL-3.0%+4.7%
1000 mg injectionNot priced this week
2.5 mg tablet$0.1632$4.90 / 30 tablets+3.5%+3.8%

The lowest cost per tablet is 2.5 mg tablet at $0.1632. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Brand names of methotrexate

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

In shortage15 products are short or being discontinued
1 ongoing recall14 recalls on record, latest Aug 14, 2024

Shortages

  • Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05)Hospira, Inc., a Pfizer Company · Unavailable · Reason: Other · Updated Nov 9, 2026Next Delivery: July 2027; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
  • Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)Fresenius Kabi USA, LLC · Available · Updated Nov 3, 2026Check wholesaler for inventory
  • Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)Fresenius Kabi USA, LLC · Available · Updated Nov 3, 2026Check wholesaler for inventory
  • Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)Accord Healthcare Inc. · Unavailable · Reason: Other · Updated Nov 2, 2026Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: Jan 2027
  • Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)Teva Pharmaceuticals USA, Inc. · Limited Availability · Reason: Other · Updated Nov 2, 2026Estimated recovery: TBD
  • Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)Accord Healthcare Inc. · Available · Updated Nov 2, 2026
  • Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)Teva Pharmaceuticals USA, Inc. · Limited Availability · Reason: Other · Updated Nov 2, 2026Estimated recovery: TBD

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 14 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for methotrexate? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedOctober 30, 2026
Version20 of 14
EffectiveOct 27, 2026
Read the label

These highlights do not include all the information needed to use METHOTREXATE INJECTION safely and effectively. See full prescribing information for METHOTREXATE INJECTION. METHOTREXATE injection, for intravenous, intramuscular, subcutaneous, or intrathecal use Initial U.S. Approval: 1953

This drug has a boxed warning

WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS

•

Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)].

•

Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.2)].

•

Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available [see Dosage and Administration (2.1) and Warnings and Precautions (5.3)].

•

Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate [see Warnings and Precautions (5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10, 5.11)].

WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS

See full prescribing information for complete boxed warning.

•

Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. Use in non-neoplastic diseases is contraindicated during pregnancy. Advise females and males of reproductive potential to use effective contraception during and after treatment with Methotrexate Injection. (4, 5.1, 8.1, 8.3)

•

Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis. (4, 5.2)

•

Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants, and for intrathecal use. Do not use benzyl alcohol-containing formulations for high-dose regimens unless immediate treatment is required and preservative-free formulations are not available. (2.1, 5.3)

•

Other serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, kidneys, liver, nervous system, gastrointestinal tract, lungs, and skin. Withhold or discontinue Methotrexate Injection as appropriate. (5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10, 5.11)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA011719 · Hospira
First approved
August 10, 1959 (67 years ago)
Latest approved change
October 15, 2026
Approved label
PDF, Oct 20, 2026
Generic makers
16 approved generic applications on the market

Methotrexate questions

How much does methotrexate cost without insurance?

Pharmacies pay about $4.90 for 30 tablets of methotrexate 2.5 mg tablet ($0.1632 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $16.14. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of methotrexate?

Methotrexate is sold as Rasuvo, Trexall, Xatmep, Otrexup. The generic has the same active ingredient and usually costs far less.

Is methotrexate in shortage?

Yes. 15 products are listed as in shortage or being discontinued (unavailable). See which ones.

Has methotrexate been recalled?

14 recalls on record, 1 ongoing. Recalls name specific lots - check yours.

When did the methotrexate label last change?

The official label was last updated on October 30, 2026 (version 20). See what changed.

Talk about methotrexate

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.